MCID: MYL006
MIFTS: 68

Myeloid Leukemia

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases, Genetic diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 53 29 55 15 73
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12
Leukemia, Myeloid 76

Classifications:



Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to cytogenetically normal acute myeloid leukemia and core binding factor acute myeloid leukemia. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene
LncRNAs MONC and MIR100HG are regulators of hematopoiesis and oncogenes in the development of myeloid leukemia
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are NF-kappaB Signaling and Pathways in cancer. The drugs Bosulif and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include myeloid tissue, myeloid and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23) Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 35.1 CEBPA FLT3 NPM1
2 core binding factor acute myeloid leukemia 34.8 CBFB CEBPA FLT3 KIT RUNX1
3 philadelphia-negative chronic myeloid leukemia 34.6 ABL1 BCR
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.3 CBFB ETV6 FLT3 KIT MYH11 RUNX1
5 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.1 CEBPA FLT3 KIT RUNX1 RUNX1T1
6 acute promyelocytic leukemia 34.0 CEBPA FLT3 NPM1 RUNX1
7 acute myeloblastic leukemia with maturation 33.9 FLT3 KIT NPM1
8 myeloid sarcoma 33.3 FLT3 KIT NPM1
9 myeloproliferative neoplasm 33.1 ABL1 BCR KIT PTPN11
10 leukemia, chronic myeloid 32.9 ABL1 BCR ETV6 FLT3 GATA2 KIT
11 leukemia 31.9 ABL1 BCR CEBPA ETV6 FLT3 KIT
12 myelodysplastic syndrome 31.7 ABL1 CEBPA ETV6 FLT3 GATA2 KIT
13 chronic myelomonocytic leukemia 31.6 ETV6 FLT3 KIT RUNX1
14 acute leukemia 31.6 CEBPA ETV6 FLT3 KIT RUNX1
15 leukemia, acute lymphoblastic 31.6 ABL1 BCR ETV6 FLT3 RUNX1
16 leukemia, acute myeloid 31.5 ABL1 BCR CBFB CEBPA ETV6 FLT3
17 lymphoblastic leukemia 31.3 ABL1 BCR ETV6 FLT3 PTPN11 RUNX1
18 mn1 31.2 ETV6 FLT3
19 chronic eosinophilic leukemia 30.9 ABL1 FLT3 KIT
20 aleukemic leukemia cutis 30.8 FLT3 MYH11 NPM1 RUNX1
21 acute lymphocytic leukemia 30.8 BCR ETV6 MCL1 RUNX1
22 platelet disorder, familial, with associated myeloid malignancy 30.6 ETV6 RUNX1
23 8p11 myeloproliferative syndrome 30.6 BCR FLT3 KIT RUNX1
24 lymphoid leukemia 30.5 ETV6 FLT3
25 childhood leukemia 30.3 ABL1 ETV6 PTPN11 RUNX1
26 alk-positive anaplastic large cell lymphoma 30.3 MCL1 NPM1
27 precursor t-cell acute lymphoblastic leukemia 30.2 ABL1 BCR ETV6 FLT3 NUP98
28 hematologic cancer 28.1 ABL1 BCR ETV6 FLT3 GATA2 KIT
29 atypical chronic myeloid leukemia 12.5
30 familial acute myeloid leukemia with mutated cebpa 12.3
31 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.1
32 acute myeloid leukemia with minimal differentiation 12.1
33 acute myeloid leukemia with t(9;11)(p22;q23) 12.1
34 acute myeloid leukemia with t(6;9)(p23;q34) 12.1
35 acute myeloid leukemia with 11q23 abnormalities 12.1
36 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.1
37 cebpa-associated familial acute myeloid leukemia 12.1
38 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 12.1
39 acute myeloid leukemia with recurrent genetic anomaly 12.0
40 unclassified acute myeloid leukemia 12.0
41 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.0
42 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 12.0
43 acute myeloid leukemia with npm1 somatic mutations 12.0
44 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.0
45 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.0
46 megakaryocytic leukemia 11.9
47 acute erythroid leukemia 11.8
48 mast-cell leukemia 11.5
49 pdgfrb-associated chronic eosinophilic leukemia 11.5
50 essential thrombocythemia 11.5

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.31 BCR CBFB ABL1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.31 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.31 CBFB ABL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.31 BCR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.31 CEBPA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.31 BCR CBFB CEBPA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.31 ABL1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.31 BCR
9 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.31 CBFB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.31 ABL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.31 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.31 KIT ABL1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.31 BCR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.31 BCR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.31 CBFB
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.31 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.31 CBFB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.31 BCR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.31 BCR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.31 BCR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.31 ABL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.31 KIT ABL1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.31 KIT CBFB
24 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.31 ABL1 CEBPA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.31 ABL1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.31 CBFB
27 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.31 ABL1 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.31 KIT CBFB ABL1 CEBPA BCR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.31 CBFB
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.31 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.31 KIT
32 Decreased substrate adherent cell growth GR00193-A-1 9.73 KIT
33 Decreased substrate adherent cell growth GR00193-A-2 9.73 ABL1 KIT
34 Decreased substrate adherent cell growth GR00193-A-4 9.73 ABL1 FLT3 KIT
35 Increased shRNA abundance GR00327-A 9.55 MCL1 CEBPA FLT3 MYH11 PTPN11
36 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.1 MCL1 GATA2 MLF1 NUP98 RUNX1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 BCR CBFB ABL1 CEBPA MCL1 GATA2
2 growth/size/body region MP:0005378 10.37 BCR CBFB ABL1 CEBPA GATA2 ETV6
3 cardiovascular system MP:0005385 10.34 CEBPA CBFB ABL1 GATA2 ETV6 KIT
4 hematopoietic system MP:0005397 10.32 CBFB ETV6 ABL1 CEBPA BCR MCL1
5 embryo MP:0005380 10.26 CBFB ABL1 MCL1 GATA2 ETV6 KIT
6 immune system MP:0005387 10.25 CEBPA BCR CBFB ABL1 MCL1 ETV6
7 homeostasis/metabolism MP:0005376 10.23 BCR CEBPA CBFB ABL1 KIT FLT3
8 mortality/aging MP:0010768 10.22 CBFB ETV6 ABL1 CEBPA BCR MCL1
9 endocrine/exocrine gland MP:0005379 10.21 CEBPA CBFB ABL1 FLT3 MCL1 GATA2
10 digestive/alimentary MP:0005381 10.19 CEBPA BCR CBFB ABL1 ETV6 KIT
11 integument MP:0010771 10.14 CEBPA CBFB MCL1 ETV6 KIT NPM1
12 liver/biliary system MP:0005370 10.07 BCR CBFB ABL1 CEBPA GATA2 KIT
13 neoplasm MP:0002006 9.91 CBFB CEBPA ETV6 KIT FLT3 NPM1
14 normal MP:0002873 9.73 CBFB ETV6 ABL1 CEBPA BCR MCL1
15 no phenotypic analysis MP:0003012 9.7 CEBPA CBFB FLT3 ETV6 KIT PTPN11
16 respiratory system MP:0005388 9.23 CEBPA CBFB ABL1 KIT MYH11 PTPN11

Drugs & Therapeutics for Myeloid Leukemia

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
2
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
3
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
4
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
5
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
6
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
7
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
8
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 678)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
6
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
7
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
8
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
9
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
11
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
13
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
14
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
15
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 20830-81-3 30323
16
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
17
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
18
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
19
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
20
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
21
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
22
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
23
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
24
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
25
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
26
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
27 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
29
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 5280795
30
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
31
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
32
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
33 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
35 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 topoisomerase I inhibitors Phase 4,Phase 2,Phase 1
39 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Gemtuzumab Phase 4,Phase 2,Phase 3,Phase 1
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 3021)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
7 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
8 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
9 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
10 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
11 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
12 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
13 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
14 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
15 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
16 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
17 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
18 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
19 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
20 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
21 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
22 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
23 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
24 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
25 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
26 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
27 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
28 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
29 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
30 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
31 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
32 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
33 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
34 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
35 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
36 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
37 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
38 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
39 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
40 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
41 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
42 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Recruiting NCT02027064 Phase 4 Interferon-alpha
43 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
44 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
45 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
46 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
47 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
48 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
49 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
50 A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

19
Myeloid Tissue

MalaCards organs/tissues related to Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Kidney

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 7415)
# Title Authors Year
1
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )
2018
2
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
3
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
4
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )
2018
5
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
6
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
7
Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation. ( 29970518 )
2018
8
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
9
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )
2018
10
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia. ( 29964149 )
2018
11
Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )
2018
12
MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )
2018
13
Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )
2018
14
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )
2018
15
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
16
Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )
2018
17
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
18
Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )
2018
19
Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )
2018
20
Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )
2018
21
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )
2018
22
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )
2018
23
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )
2018
24
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. ( 28776669 )
2018
25
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
26
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
27
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. ( 29151104 )
2018
28
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )
2018
29
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
30
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )
2018
31
Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )
2018
32
Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )
2018
33
Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )
2018
34
Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )
2018
35
A typical atypical chronic myeloid leukemia. ( 29744086 )
2018
36
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )
2018
37
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
38
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )
2018
39
Downregulated miR-217A expression predicts a poor outcome in acuteA myeloid leukemia. ( 29439315 )
2018
40
<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )
2018
41
Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )
2018
42
Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes. ( 29330024 )
2018
43
Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis. ( 29438720 )
2018
44
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. ( 29976748 )
2018
45
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( 29119643 )
2018
46
Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )
2018
47
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. ( 29455651 )
2018
48
NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )
2018
49
Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )
2018
50
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. ( 29976734 )
2018

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 ABL1 CBFB CEBPA GATA2 MCL1 MECOM
2 protein-containing complex GO:0032991 9.55 ABL1 BCR FLT3 NPM1 PTPN11
3 nucleus GO:0005634 9.5 ABL1 CBFB CEBPA ETV6 FLT3 GATA2

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.97 ABL1 ETV6 FLT3 GATA2 KIT MCL1
2 cytokine-mediated signaling pathway GO:0019221 9.89 CEBPA FLT3 KIT MCL1 PTPN11
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 ABL1 FLT3 KIT PTPN11
4 protein autophosphorylation GO:0046777 9.83 ABL1 BCR FLT3 KIT
5 peptidyl-tyrosine phosphorylation GO:0018108 9.81 ABL1 BCR FLT3 KIT
6 transcription by RNA polymerase II GO:0006366 9.8 CBFB CEBPA ETV6 GATA2 NPM1 NUP98
7 regulation of hematopoietic stem cell differentiation GO:1902036 9.73 ABL1 CBFB GATA2 RUNX1
8 cell maturation GO:0048469 9.65 CBFB CEBPA GATA2
9 cell fate determination GO:0001709 9.64 GATA2 MCL1
10 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.63 CBFB RUNX1
11 platelet-derived growth factor receptor signaling pathway GO:0048008 9.63 ABL1 BCR PTPN11
12 regulation of keratinocyte differentiation GO:0045616 9.62 CBFB RUNX1
13 regulation of regulatory T cell differentiation GO:0045589 9.62 CBFB RUNX1
14 hemopoiesis GO:0030097 9.62 FLT3 GATA2 KIT RUNX1
15 negative regulation of programmed cell death GO:0043069 9.61 KIT MECOM
16 megakaryocyte development GO:0035855 9.61 KIT PTPN11
17 regulation of bicellular tight junction assembly GO:2000810 9.6 CBFB RUNX1
18 regulation of myeloid cell differentiation GO:0045637 9.58 CBFB RUNX1
19 regulation of response to DNA damage stimulus GO:2001020 9.57 ABL1 MCL1
20 regulation of B cell receptor signaling pathway GO:0050855 9.56 CBFB RUNX1
21 regulation of cytokine-mediated signaling pathway GO:0001959 9.55 CBFB RUNX1
22 Bergmann glial cell differentiation GO:0060020 9.54 ABL1 PTPN11
23 definitive hemopoiesis GO:0060216 9.33 BCR CBFB GATA2
24 hematopoietic stem cell proliferation GO:0071425 9.13 ETV6 MECOM RUNX1
25 myeloid progenitor cell differentiation GO:0002318 8.8 FLT3 KIT MLF1
26 regulation of transcription, DNA-templated GO:0006355 10.29 ABL1 CEBPA ETV6 GATA2 MECOM MLF1
27 regulation of transcription by RNA polymerase II GO:0006357 10.14 CBFB CEBPA ETV6 KIT MECOM NPM1
28 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 CBFB CEBPA ETV6 GATA2 MECOM NPM1

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ABL1 BCR CBFB CEBPA ETV6 FLT3
2 DNA binding transcription factor activity GO:0003700 9.8 CBFB CEBPA ETV6 GATA2 MECOM RUNX1
3 protein domain specific binding GO:0019904 9.62 ABL1 ETV6 MLF1 PTPN11
4 protein tyrosine kinase activity GO:0004713 9.46 ABL1 BCR FLT3 KIT
5 DNA binding GO:0003677 9.32 ABL1 CBFB CEBPA ETV6 GATA2 MECOM

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....